Nuvalent (NUVL) Shares Outstanding (2020 - 2026)
Nuvalent's (NUVL) quarterly Shares Outstanding (Entity) came in at $73.4 million in Q1 2026, up 10.74% YoY from $66.3 million in Q1 2025, and up 0.88% on a QoQ basis from $72.8 million in Q4 2025.
Analysis
Nuvalent (NUVL) Shares Outstanding (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Shares Outstanding (Entity) data on file, last reported at $73.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 10.74% year-over-year to $73.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.4 million (up 10.74% YoY) and the FY2025 annual result came in at $72.8 million, up 10.46% from the prior year.
- Shares Outstanding (Entity) improved to $73.4 million in Q1 2026, from $72.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $73.4 million in Q1 2026 to a low of $42.9 million in Q1 2022.
- A 5-year average of $58.2 million and a median of $59.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 1270.93% — and 2025, when it climbed 2.05%.
- Tracing NUVL's Shares Outstanding (Entity) over 5 years: stood at $51.2 million in 2022, then rose by 14.44% to $58.6 million in 2023, then climbed by 12.42% to $65.9 million in 2024, then climbed by 10.46% to $72.8 million in 2025, then advanced by 0.88% to $73.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $73.4 million (Q1 2026), $72.8 million (Q4 2025), and $66.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 78.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 78.67 Mn |
| Dec 31, 2025 | 72.69 Mn |
| Sep 30, 2025 | 72.14 Mn |
| Jun 30, 2025 | 71.84 Mn |
| Mar 31, 2025 | 71.61 Mn |
| Dec 31, 2024 | 66.41 Mn |
| Sep 30, 2024 | 65.68 Mn |
| Jun 30, 2024 | 64.61 Mn |
| Mar 31, 2024 | 64.15 Mn |
| Dec 31, 2023 | 58.22 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 56.87 Mn |
| Mar 31, 2023 | 56.70 Mn |
| Dec 31, 2022 | 49.67 Mn |
| Sep 30, 2022 | 48.41 Mn |
| Jun 30, 2022 | 48.32 Mn |
| Mar 31, 2022 | 48.28 Mn |
| Dec 31, 2021 | 21.78 Mn |
| Sep 30, 2021 | 32.07 Mn |
| Jun 30, 2021 | 3.11 Mn |